BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Oliver's mTOR Atlas//Events//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:asco-annual-meeting-2027@mtor-atlas.org
DTSTAMP:20261102T142257Z
DTSTART;VALUE=DATE:20270604
DTEND;VALUE=DATE:20270609
SUMMARY:ASCO Annual Meeting 2027
LOCATION:McCormick Place Convention Center\, Chicago\, IL\, USA
DESCRIPTION:The largest clinical oncology meeting worldwide\; where practic
 e-changing trial results are first presented.\n\nWhy it matters for mTOR (
 ★★): Where mTOR inhibition meets clinical endpoints in humans. The eve
 rolimus registration trials (RECORD-1 in renal cell carcinoma\, BOLERO-2 i
 n breast cancer\, RADIANT-3 in neuroendocrine tumours - Motzer RJ\, Baselg
 a J\, Yao JC\, all Atlas authors) were reported at ASCO\, as were the RMC-
 5552 combination findings. The purest expression of the Atlas's translatio
 n-gap axis: mTOR inhibitors that work in mice tested against hard human en
 dpoints.\n\nConference site: https://www.asco.org/annual-meeting\n\nIn Oli
 ver's mTOR Atlas: https://mtor-atlas.org/events/#ev-asco-annual-meeting-20
 27
URL:https://www.asco.org/annual-meeting
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR